Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer A Locke

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
The Prostate|October 30, 2009
Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft modelCarlos G Leon, Jennifer A Locke, Hans H Adomat, et al.
The Prostate|October 1, 2009
Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistanceJennifer A Locke, Emma S Tomlinson Guns, Melanie L Lehman, et al.
Urology|February 7, 2021
AUTHOR REPLYElaine J Redmond, Genevieve Nadeau, Le-Mai Tu, et al.
Urology|November 12, 2020
Multicentered Assessment of Clinical Outcomes and Factors Associated With Failure of the Adjustable TransObturator Male System (ATOMS)Elaine J Redmond, Genevieve Nadeau, Le-Mai Tu, et al.
The Prostate|January 4, 2012
Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancerJennifer A Locke, Gaetano Zafarana, Chad A Malloff, et al.
Clinical Genitourinary Cancer|November 22, 2015
Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative CisplatinJennifer A Locke, Gregory Russell Pond, Guru Sonpavde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2011
NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapyJennifer A Locke, Gaetano Zafarana, Adrian S Ishkanian, et al.
Cancer|January 28, 2012
Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapyGaetano Zafarana, Adrian S Ishkanian, Chad A Malloff, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 25, 2018
Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinomaJennifer A Locke, Reza Hamidizadeh, Wassim Kassouf, et al.
Oncotarget|May 8, 2018
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN studyJacob A Gordon, Carlo Buonerba, Gregory Pond, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
The Prostate|October 30, 2009
Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft modelCarlos G Leon, Jennifer A Locke, Hans H Adomat, et al.
The Prostate|October 1, 2009
Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistanceJennifer A Locke, Emma S Tomlinson Guns, Melanie L Lehman, et al.
Urology|February 7, 2021
AUTHOR REPLYElaine J Redmond, Genevieve Nadeau, Le-Mai Tu, et al.
Urology|November 12, 2020
Multicentered Assessment of Clinical Outcomes and Factors Associated With Failure of the Adjustable TransObturator Male System (ATOMS)Elaine J Redmond, Genevieve Nadeau, Le-Mai Tu, et al.
The Prostate|January 4, 2012
Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancerJennifer A Locke, Gaetano Zafarana, Chad A Malloff, et al.
Clinical Genitourinary Cancer|November 22, 2015
Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative CisplatinJennifer A Locke, Gregory Russell Pond, Guru Sonpavde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2011
NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapyJennifer A Locke, Gaetano Zafarana, Adrian S Ishkanian, et al.
Cancer|January 28, 2012
Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapyGaetano Zafarana, Adrian S Ishkanian, Chad A Malloff, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 25, 2018
Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinomaJennifer A Locke, Reza Hamidizadeh, Wassim Kassouf, et al.
Oncotarget|May 8, 2018
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN studyJacob A Gordon, Carlo Buonerba, Gregory Pond, et al.
Pageof 4